Iovance Biotherapeutics, Inc. (0JDK.L)
USD 7.6
(-2.69%)
USD 7.6
(-2.69%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -113.88 Million USD | 73.32% |
| 2022 | -146.28 Million USD | -2084.01% |
| 2021 | -6.69 Million USD | 57.26% |
| 2020 | -15.67 Million USD | -534.67% |
| 2019 | -2.46 Million USD | 96.99% |
| 2018 | -82.15 Million USD | 43.49% |
| 2017 | -145.37 Million USD | -36.22% |
| 2016 | -106.71 Million USD | -217.73% |
| 2015 | -33.58 Million USD | 25.21% |
| 2014 | -44.9 Million USD | -128.29% |
| 2013 | -19.67 Million USD | -393543.54% |
| 2012 | 5000.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -49.81 Million USD | -27.66% |
| 2024 Q2 | -227.67 Million USD | -195.21% |
| 2023 Q3 | -188.24 Million USD | -26.08% |
| 2023 Q1 | -460.25 Million USD | -214.63% |
| 2023 Q2 | -149.3 Million USD | 67.56% |
| 2023 FY | -39.02 Million USD | 73.32% |
| 2023 Q4 | -39.02 Million USD | 79.27% |
| 2022 Q4 | -146.28 Million USD | -282.42% |
| 2022 Q3 | -38.25 Million USD | -38.61% |
| 2022 Q2 | -27.59 Million USD | -121.37% |
| 2022 FY | -146.28 Million USD | -2084.01% |
| 2022 Q1 | -12.46 Million USD | -86.12% |
| 2021 Q3 | 13.75 Million USD | 145.11% |
| 2021 Q4 | -6.69 Million USD | -148.7% |
| 2021 Q1 | -77.95 Million USD | -255.08% |
| 2021 FY | -6.69 Million USD | 57.26% |
| 2021 Q2 | -30.49 Million USD | 60.89% |
| 2020 Q3 | -64.59 Million USD | 59.27% |
| 2020 Q4 | -21.95 Million USD | 66.01% |
| 2020 FY | -15.67 Million USD | -534.67% |
| 2020 Q1 | -49.45 Million USD | -408.71% |
| 2020 Q2 | -158.61 Million USD | -220.74% |
| 2019 Q4 | -9.72 Million USD | 70.43% |
| 2019 Q3 | -32.87 Million USD | 54.53% |
| 2019 Q2 | -72.29 Million USD | -45.43% |
| 2019 Q1 | -49.71 Million USD | 39.49% |
| 2019 FY | -2.46 Million USD | 96.99% |
| 2018 Q4 | -82.15 Million USD | -1.75% |
| 2018 Q3 | -80.73 Million USD | 67.18% |
| 2018 Q2 | -246.01 Million USD | 17.19% |
| 2018 Q1 | -297.08 Million USD | -104.36% |
| 2018 FY | -82.15 Million USD | 43.49% |
| 2017 Q4 | -145.37 Million USD | 11.02% |
| 2017 FY | -145.37 Million USD | -36.22% |
| 2017 Q3 | -163.38 Million USD | -42.96% |
| 2017 Q1 | -107.09 Million USD | -0.36% |
| 2017 Q2 | -114.28 Million USD | -6.71% |
| 2016 Q3 | -92.89 Million USD | 8.23% |
| 2016 FY | -106.71 Million USD | -217.73% |
| 2016 Q4 | -106.71 Million USD | -14.88% |
| 2016 Q2 | -101.22 Million USD | -1031.86% |
| 2016 Q1 | -8.94 Million USD | 73.37% |
| 2015 Q2 | -12.55 Million USD | 88.72% |
| 2015 FY | -33.58 Million USD | 25.21% |
| 2015 Q3 | -10.21 Million USD | 18.69% |
| 2015 Q4 | -33.58 Million USD | -228.96% |
| 2015 Q1 | -111.28 Million USD | -147.79% |
| 2014 Q3 | -17.18 Million USD | 6.78% |
| 2014 Q4 | -44.9 Million USD | -161.26% |
| 2014 Q1 | -17.94 Million USD | 8.79% |
| 2014 Q2 | -18.44 Million USD | -2.77% |
| 2014 FY | -44.9 Million USD | -128.29% |
| 2013 FY | -19.67 Million USD | -393543.54% |
| 2013 Q2 | -569.58 Thousand USD | -108.39% |
| 2013 Q1 | 6.78 Million USD | 135625.0% |
| 2013 Q3 | -129.8 Thousand USD | 77.21% |
| 2013 Q4 | -19.67 Million USD | -15055.29% |
| 2012 FY | 5000.00 USD | 0.0% |
| 2012 Q4 | 5000.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | -30.731% |
| Dynavax Technologies Corporation | 106.63 Million USD | 206.802% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -239.69% |
| Perrigo Company plc | 3.32 Billion USD | 103.428% |
| Illumina, Inc. | 1.21 Billion USD | 109.381% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.424% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 101.383% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.886% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 178.502% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -320.251% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 1684.639% |
| Waters Corporation | 1.96 Billion USD | 105.809% |
| Biogen Inc. | 6.28 Billion USD | 101.811% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -1504.056% |
| Evolus, Inc. | 63.7 Million USD | 278.766% |
| Adicet Bio, Inc. | -142 Million USD | 19.802% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -1163.177% |
| bluebird bio, Inc. | 108.57 Million USD | 204.897% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 124.828% |
| FibroGen, Inc. | 56.76 Million USD | 300.624% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 109.947% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 1734.425% |
| Homology Medicines, Inc. | 18.43 Million USD | 717.714% |
| Geron Corporation | 14.76 Million USD | 871.547% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 107.184% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 157.5% |
| Myriad Genetics, Inc. | 88.1 Million USD | 229.271% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -109.909% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | -2.232% |
| Zoetis Inc. | 4.76 Billion USD | 102.392% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -1030.851% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 105.429% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 130.07% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 98.809% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -681.554% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 110.803% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 457.184% |
| Verastem, Inc. | -37.27 Million USD | -205.51% |
| Nektar Therapeutics | 210.24 Million USD | 154.17% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 43.005% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -209.445% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 111.761% |
| OPKO Health, Inc. | 230.68 Million USD | 149.37% |
| Exelixis, Inc. | -73.05 Million USD | -55.904% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 164.235% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 15.888% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 24.589% |
| uniQure N.V. | -102.95 Million USD | -10.624% |
| Imunon, Inc. | -4.69 Million USD | -2323.524% |
| Blueprint Medicines Corporation | 702.83 Million USD | 116.204% |
| Insmed Incorporated | 721.62 Million USD | 115.782% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 108.248% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -264.827% |
| TG Therapeutics, Inc. | 17.86 Million USD | 737.599% |
| Incyte Corporation | -3.17 Billion USD | 96.413% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 114.872% |